{"protocolSection": {"identificationModule": {"nctId": "NCT02091986", "orgStudyIdInfo": {"id": "D589GC00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg and Symbicort pMDI 80/4.5 \u03bcg, Compared With Budesonide pMDI 80 \u03bcg", "officialTitle": "A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 \u03bcg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 \u03bcg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years With Asthma", "acronym": "CHASE 3"}, "statusModule": {"statusVerifiedDate": "2017-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-04"}, "primaryCompletionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-03-18", "studyFirstSubmitQcDate": "2014-03-18", "studyFirstPostDateStruct": {"date": "2014-03-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-10-11", "resultsFirstSubmitQcDate": "2017-02-24", "resultsFirstPostDateStruct": {"date": "2017-04-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-02-24", "lastUpdatePostDateStruct": {"date": "2017-04-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg and Symbicort pMDI 80/4.5 \u03bcg, Compared with Budesonide pMDI 80 \u03bcg, 2 Actuations Twice Daily, in Children Ages 6 to \\<12 Years with Asthma during 12 weeks.", "detailedDescription": "A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 \u03bcg, 2 Actuations Twice Daily, Compared with Budesonide pMDI 80 \u03bcg, 2 Actuations Twice Daily, in Children Ages 6 to \\<12 Years with Asthma"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma, children, budesonide pMDI"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 882, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Symbicort pMDI 80/2.25 \u00b5g", "type": "ACTIVE_COMPARATOR", "description": "Budesonide/formoterol pMDI 80/2.25 \u00b5g, 2 acuations twice daily", "interventionNames": ["Drug: Symbicort pMDI"]}, {"label": "Symbicort pMDI 80/4.5\u00b5g", "type": "ACTIVE_COMPARATOR", "description": "Budesonide/formoterol pMDI 80/4.5\u00b5g, 2 acuations twice daily", "interventionNames": ["Drug: Symbicort pMDI"]}, {"label": "Budesonide pMDI", "type": "ACTIVE_COMPARATOR", "description": "Budesonide pMDI 80\u00b5g, 2 acuations twice daily", "interventionNames": ["Other: Budesonide pMDI"]}], "interventions": [{"type": "DRUG", "name": "Symbicort pMDI", "description": "Budesonide/formoterol pMDI 80/2.25 \u00b5g, 2 acuations twice daily", "armGroupLabels": ["Symbicort pMDI 80/2.25 \u00b5g"]}, {"type": "DRUG", "name": "Symbicort pMDI", "description": "Budesonide/formoterol pMDI 80/4.5\u00b5g, 2 acuations twice daily", "armGroupLabels": ["Symbicort pMDI 80/4.5\u00b5g"]}, {"type": "OTHER", "name": "Budesonide pMDI", "description": "Budesonide pMDI 80\u00b5g, 2 acuations twice daily", "armGroupLabels": ["Budesonide pMDI"], "otherNames": ["Active comparator"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 12 in 1h Post-dose FEV1", "description": "1h post-dose FEV1 is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 12 in 1h Post-dose PEF", "description": "1h post-dose PEF is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in 1h Post-dose FEF25-75", "description": "1h post-dose FEF25-75 is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in 1h Post-dose FVC", "description": "1h post-dose FVC is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in Pre-dose FEV1", "description": "Pre-dose FEV1 is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in Pre-dose PEF", "description": "Pre-dose PEF is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in Pre-dose FEF25-75", "description": "Pre-dose FEF25-75 is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in Pre-dose FVC", "description": "Pre-dose FVC is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Week 12 in 15 Min Post-dose FEV1", "description": "15 min Post-dose FEV1 is defined as the 15 min post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to End of Study Average in Total Asthma Symptoms", "description": "End of study average is defined as the average of available records from 7 days before up to and including the day prior to withdrawal from study or Week 12, minus the baseline measurement at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).\n\nPatient to record his/her asthma symptom score twice daily. The following rating scales are to be used: 0 = None; no symptoms of asthma\n\n1. = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated\n2. = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep\n3. = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep\n\nTotal asthma symptom score is derived as the sum of the daytime score plus the score from the previous nighttime, ie possible range (0 to 6).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to End of Study Average in % of Night Time Awakenings Due to Asthma Symptoms", "description": "End of study average is defined as the percentage of nighttime awakenings due to asthma symptoms from 6 days before up to and additionally including the morning of withdrawal from study or Week 12, minus the baseline measurement at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to End of Study Average in Total Daily Reliever Medication", "description": "End of study average is defined as the average of available records from 7 days before up to and including the day prior to withdrawal from study or Week 12, minus the baseline measurement at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).", "timeFrame": "Week 0 (baseline), Week 12"}, {"measure": "Change From Baseline to Study Period Average in Overall PAQLQ Score", "description": "Study period average is defined as the average of the post-baseline values during the study taken after first dose of investigational product up to and including withdrawal from study or Week 12, minus the baseline assessment at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).\n\nThe PAQLQ(S) is a 23-item patient-reported questionnaire, each one reported on a 7-point scale (e.g. 1 = extremely bothered/all of the time; 7 = not bothered/none of the time). The PAQLQ(S) generates an overall score, as well as 3 domain scores: activity limitations (5 items), symptoms (10 items) and emotional function (8 items). The overall score will be calculated as the mean of the responses to each of the 23 questions (ie the range of 1-7, where higher scores indicate better quality of life). If any of the domain scores are missing, no total score will be calculated.", "timeFrame": "Week 0 (baseline), week 4, week 8, week 12"}, {"measure": "Number of Patients With an Asthma Exacerbation During Study", "description": "Number of patients that experienced an asthma exacerbation that required either emergency room treatment, hospitalization, systemic steroids, or an increase in, or additional asthma maintenance medication, during the study.", "timeFrame": "Week 0 (baseline) up to Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has a documented clinical diagnosis of asthma defined by the ATS for at least 6 months prior to Visit 2\n* Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of 60% to 100% of predicted normal\n* Demonstrated reversibility of clinic FEV1 of \u226512% from pre -albuterol/salbutamol level within 15 to 30 minutes after administration of a standard dose of albuterol/salbutamol.\n\nExclusion Criteria:\n\n* Have been hospitalized at least once or required emergency treatment more than once for an asthma-related condition during the 6 months prior to Visit 1\n* Have required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 6 weeks prior to Visit 1", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "David S Pearlman, MD", "affiliation": "Colorado Allergy Asthma Centers, PC, US", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Carin Jorup, MD", "affiliation": "AstraZeneca M\u00f6lndal, Sweden", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Hoover", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.40539, "lon": -86.81138}}, {"facility": "Research Site", "city": "Montgomery", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 32.36681, "lon": -86.29997}}, {"facility": "Research Site", "city": "Gilbert", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Research Site", "city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Research Site", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Research Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Research Site", "city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Research Site", "city": "Newport Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Research Site", "city": "Ontario", "state": "California", "country": "United States", "geoPoint": {"lat": 34.06334, "lon": -117.65089}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Walnut Creek", "state": "California", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Aventura", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Research Site", "city": "Coral Gables", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Research Site", "city": "Fort Walton Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.42077, "lon": -86.61939}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Homestead", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.46872, "lon": -80.47756}}, {"facility": "Research Site", "city": "Jacksonville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Research Site", "city": "Largo", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Williston", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.38747, "lon": -82.44677}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "Stockbridge", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Research Site", "city": "Lenexa", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 38.95362, "lon": -94.73357}}, {"facility": "Research Site", "city": "Waldorf", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.62456, "lon": -76.93914}}, {"facility": "Research Site", "city": "Plymouth", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 45.01052, "lon": -93.45551}}, {"facility": "Research Site", "city": "Bellevue", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Research Site", "city": "Verona", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -74.24015}}, {"facility": "Research Site", "city": "Albuquerque", "state": "New Mexico", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Research Site", "city": "Rockville Centre", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.65871, "lon": -73.64124}}, {"facility": "Research Site", "city": "Watertown", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.97478, "lon": -75.91076}}, {"facility": "Research Site", "city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Research Site", "city": "Canton", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Toledo", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Research Site", "city": "Edmond", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Gresham", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.49818, "lon": -122.43148}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Research Site", "city": "North Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "West Columbia", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.99349, "lon": -81.07398}}, {"facility": "Research Site", "city": "Allen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.10317, "lon": -96.67055}}, {"facility": "Research Site", "city": "Baytown", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.7355, "lon": -94.97743}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "Fort Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Kerville", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.04886, "lon": -99.13887}}, {"facility": "Research Site", "city": "Richmond", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.58218, "lon": -95.76078}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Research Site", "city": "Murray", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Research Site", "city": "Fairfax", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Research Site", "city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Research Site", "city": "Washington", "state": "Washington", "country": "United States"}, {"facility": "Research Site", "city": "Cuautitlan Izcalli", "country": "Mexico", "geoPoint": {"lat": 19.64388, "lon": -99.21598}}, {"facility": "Research Site", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Ciudad de Panama", "country": "Panama", "geoPoint": {"lat": 8.9936, "lon": -79.51973}}, {"facility": "Research Site", "city": "David Chiriqui", "country": "Panama"}, {"facility": "Research Site", "city": "Panama", "country": "Panama", "geoPoint": {"lat": 8.9936, "lon": -79.51973}}, {"facility": "Research Site", "city": "Banska Bystrica", "country": "Slovakia", "geoPoint": {"lat": 48.73946, "lon": 19.15349}}, {"facility": "Research Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Research Site", "city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Research Site", "city": "Lucenec", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Research Site", "city": "Poprad", "country": "Slovakia", "geoPoint": {"lat": 49.06144, "lon": 20.29798}}, {"facility": "Research Site", "city": "Presov", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}]}, "referencesModule": {"references": [{"pmid": "28256307", "type": "DERIVED", "citation": "Pearlman DS, Eckerwall G, McLaren J, Lamarca R, Puu M, Gilbert I, Jorup C, Sandin K, Lanz MJ. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years). Ann Allergy Asthma Immunol. 2017 Apr;118(4):489-499.e1. doi: 10.1016/j.anai.2017.01.020. Epub 2017 Mar 1."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The enrollment number in the protocol section denotes the number of patients screened into the trial. Out of these 882 patients screened, 279 patients were randomized into the trial. This explains the discrepancy in patient number.", "groups": [{"id": "FG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "FG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "FG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "95"}, {"groupId": "FG002", "numSubjects": "92"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "84"}, {"groupId": "FG002", "numSubjects": "84"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "7 rand in error 1 patient decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients randomized, defined as having a randomization code recorded on the demography case report form (CRF)", "groups": [{"id": "BG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "BG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "BG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "95"}, {"groupId": "BG002", "value": "92"}, {"groupId": "BG003", "value": "279"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9", "spread": "1.6"}, {"groupId": "BG001", "value": "9", "spread": "1.6"}, {"groupId": "BG002", "value": "9", "spread": "1.4"}, {"groupId": "BG003", "value": "9", "spread": "1.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "113"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "55"}, {"groupId": "BG003", "value": "166"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "106"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "60"}, {"groupId": "BG003", "value": "173"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "26"}, {"groupId": "BG003", "value": "76"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "53"}, {"groupId": "BG003", "value": "174"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "15"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38", "spread": "12.9"}, {"groupId": "BG001", "value": "38", "spread": "12.9"}, {"groupId": "BG002", "value": "40", "spread": "13.6"}, {"groupId": "BG003", "value": "39", "spread": "13.1"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "139", "spread": "11.1"}, {"groupId": "BG001", "value": "138", "spread": "10.9"}, {"groupId": "BG002", "value": "141", "spread": "10.5"}, {"groupId": "BG003", "value": "139", "spread": "10.8"}]}]}]}, {"title": "Duration of asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.8", "spread": "3.0"}, {"groupId": "BG001", "value": "5.9", "spread": "3.2"}, {"groupId": "BG002", "value": "6.2", "spread": "3.1"}, {"groupId": "BG003", "value": "5.9", "spread": "3.1"}]}]}]}, {"title": "FEV1 at randomisation", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.58", "spread": "0.42"}, {"groupId": "BG001", "value": "1.57", "spread": "0.33"}, {"groupId": "BG002", "value": "1.62", "spread": "0.36"}, {"groupId": "BG003", "value": "1.59", "spread": "0.37"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 12 in 1h Post-dose FEV1", "description": "1h post-dose FEV1 is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint.\n\nPatients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.28", "lowerLimit": "0.22", "upperLimit": "0.34"}, {"groupId": "OG001", "value": "0.24", "lowerLimit": "0.18", "upperLimit": "0.31"}, {"groupId": "OG002", "value": "0.17", "lowerLimit": "0.10", "upperLimit": "0.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.006", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline FEV1, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.063", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline FEV1, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.373", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline FEV1, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in 1h Post-dose PEF", "description": "1h post-dose PEF is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint.\n\nPatients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters per minute", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.04", "lowerLimit": "46.12", "upperLimit": "67.97"}, {"groupId": "OG001", "value": "41.14", "lowerLimit": "30.26", "upperLimit": "52.01"}, {"groupId": "OG002", "value": "31.57", "lowerLimit": "20.78", "upperLimit": "42.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.195", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.032", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in 1h Post-dose FEF25-75", "description": "1h post-dose FEF25-75 is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters per second", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.55", "lowerLimit": "0.43", "upperLimit": "0.67"}, {"groupId": "OG001", "value": "0.47", "lowerLimit": "0.35", "upperLimit": "0.59"}, {"groupId": "OG002", "value": "0.23", "lowerLimit": "0.11", "upperLimit": "0.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.326", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in 1h Post-dose FVC", "description": "1h post-dose FVC is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "lowerLimit": "0.15", "upperLimit": "0.30"}, {"groupId": "OG001", "value": "0.16", "lowerLimit": "0.09", "upperLimit": "0.23"}, {"groupId": "OG002", "value": "0.17", "lowerLimit": "0.10", "upperLimit": "0.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.276", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.759", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.165", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Pre-dose FEV1", "description": "Pre-dose FEV1 is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.04", "upperLimit": "0.17"}, {"groupId": "OG001", "value": "0.10", "lowerLimit": "0.03", "upperLimit": "0.16"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "0.03", "upperLimit": "0.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.724", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.909", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.811", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Pre-dose PEF", "description": "Pre-dose PEF is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters per minute", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.73", "lowerLimit": "16.37", "upperLimit": "39.08"}, {"groupId": "OG001", "value": "15.86", "lowerLimit": "4.39", "upperLimit": "27.33"}, {"groupId": "OG002", "value": "16.01", "lowerLimit": "4.50", "upperLimit": "27.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.134", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.985", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.128", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Pre-dose FEF25-75", "description": "Pre-dose FEF25-75 is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters per minute", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "lowerLimit": "0.01", "upperLimit": "0.24"}, {"groupId": "OG001", "value": "0.13", "lowerLimit": "0.01", "upperLimit": "0.25"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "-0.03", "upperLimit": "0.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.684", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.621", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.929", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Pre-dose FVC", "description": "Pre-dose FVC is defined as the pre-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.03", "upperLimit": "0.18"}, {"groupId": "OG001", "value": "0.11", "lowerLimit": "0.04", "upperLimit": "0.19"}, {"groupId": "OG002", "value": "0.13", "lowerLimit": "0.05", "upperLimit": "0.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.664", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.747", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.913", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in 15 Min Post-dose FEV1", "description": "15 min Post-dose FEV1 is defined as the 15 min post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "80"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "lowerLimit": "0.18", "upperLimit": "0.31"}, {"groupId": "OG001", "value": "0.19", "lowerLimit": "0.12", "upperLimit": "0.25"}, {"groupId": "OG002", "value": "0.15", "lowerLimit": "0.08", "upperLimit": "0.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.015", "statisticalMethod": "ANCOVA", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.342", "statisticalMethod": "ANCOVA", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.138", "statisticalMethod": "ANCOVA", "statisticalComment": "Baseline lung function assessment, Treatment group, Region, Age were all included as explanatory variables in the linear predictor."}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Study Average in Total Asthma Symptoms", "description": "End of study average is defined as the average of available records from 7 days before up to and including the day prior to withdrawal from study or Week 12, minus the baseline measurement at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).\n\nPatient to record his/her asthma symptom score twice daily. The following rating scales are to be used: 0 = None; no symptoms of asthma\n\n1. = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated\n2. = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep\n3. = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep\n\nTotal asthma symptom score is derived as the sum of the daytime score plus the score from the previous nighttime, ie possible range (0 to 6).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "0.73"}, {"groupId": "OG001", "value": "-0.6", "spread": "0.73"}, {"groupId": "OG002", "value": "-0.4", "spread": "0.55"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Study Average in % of Night Time Awakenings Due to Asthma Symptoms", "description": "End of study average is defined as the percentage of nighttime awakenings due to asthma symptoms from 6 days before up to and additionally including the morning of withdrawal from study or Week 12, minus the baseline measurement at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of nighttime awakenings", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "82"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.0", "spread": "29.15"}, {"groupId": "OG001", "value": "-17.3", "spread": "33.16"}, {"groupId": "OG002", "value": "-13.0", "spread": "21.87"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Study Average in Total Daily Reliever Medication", "description": "End of study average is defined as the average of available records from 7 days before up to and including the day prior to withdrawal from study or Week 12, minus the baseline measurement at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of reliever medication use", "timeFrame": "Week 0 (baseline), Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "1.75"}, {"groupId": "OG001", "value": "-1.1", "spread": "2.37"}, {"groupId": "OG002", "value": "-0.7", "spread": "1.37"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Study Period Average in Overall PAQLQ Score", "description": "Study period average is defined as the average of the post-baseline values during the study taken after first dose of investigational product up to and including withdrawal from study or Week 12, minus the baseline assessment at randomization, for patients who remain in the study (irrespective of whether IP has been discontinued).\n\nThe PAQLQ(S) is a 23-item patient-reported questionnaire, each one reported on a 7-point scale (e.g. 1 = extremely bothered/all of the time; 7 = not bothered/none of the time). The PAQLQ(S) generates an overall score, as well as 3 domain scores: activity limitations (5 items), symptoms (10 items) and emotional function (8 items). The overall score will be calculated as the mean of the responses to each of the 23 questions (ie the range of 1-7, where higher scores indicate better quality of life). If any of the domain scores are missing, no total score will be calculated.", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* the patient contributed data for at least one efficacy endpoint. Patients accounted for according to the treatment to which they were randomized.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "unit on a scale", "timeFrame": "Week 0 (baseline), week 4, week 8, week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "82"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "lowerLimit": "0.30", "upperLimit": "0.62"}, {"groupId": "OG001", "value": "0.53", "lowerLimit": "0.38", "upperLimit": "0.69"}, {"groupId": "OG002", "value": "0.62", "lowerLimit": "0.47", "upperLimit": "0.78"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.098", "statisticalMethod": "ANCOVA", "statisticalComment": "The explanatory variables included in the model are: treatment group, baseline overall PAQLQ(S) score, region and age group"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.367", "statisticalMethod": "ANCOVA", "statisticalComment": "The explanatory variables included in the model are: treatment group, baseline overall PAQLQ(S) score, region and age group"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.449", "statisticalMethod": "ANCOVA", "statisticalComment": "The explanatory variables included in the model are: treatment group, baseline overall PAQLQ(S) score, region and age group"}]}, {"type": "SECONDARY", "title": "Number of Patients With an Asthma Exacerbation During Study", "description": "Number of patients that experienced an asthma exacerbation that required either emergency room treatment, hospitalization, systemic steroids, or an increase in, or additional asthma maintenance medication, during the study.", "populationDescription": "All patients randomized who:\n\n* received at least one dose of study medication;\n* data collected after randomisation. Patients accounted for according to the treatment they actually received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Partcicipants", "timeFrame": "Week 0 (baseline) up to Week 12", "groups": [{"id": "OG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID"}, {"id": "OG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/2.25 ug x 2 BID"}, {"id": "OG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Week 0 (baseline) up to 12 weeks", "description": "Serious Adverse Events Table, Other Adverse Events Table based on all of patients rand who :\n\n* received at least 1 dose of study meds;\n* data were collected after randomization. No of part provided in the Participant Flow Module based on all patients randomized.", "eventGroups": [{"id": "EG000", "title": "Symbicort pMDI 80/4.5 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID", "seriousNumAffected": 0, "seriousNumAtRisk": 90, "otherNumAffected": 42, "otherNumAtRisk": 90}, {"id": "EG001", "title": "Symbicort pMDI 80/2.25 ug", "description": "Symbicort pMDI 80/4.5 ug x 2 BID", "seriousNumAffected": 0, "seriousNumAtRisk": 93, "otherNumAffected": 41, "otherNumAtRisk": 93}, {"id": "EG002", "title": "Budesonide pMDI 80 ug", "description": "Budesonide pMDI 80 ug x 2 BID", "seriousNumAffected": 2, "seriousNumAtRisk": 90, "otherNumAffected": 40, "otherNumAtRisk": 90}], "seriousEvents": [{"term": "Acute lymphocytic leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 90}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 90}]}, {"term": "Pyrexia", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 90}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 90}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 90}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 90}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Viral upper respiratory tract", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 93}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 90}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Global Clinical Lead G\u00f6ran Eckerwall", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}